NCT04368143 (IMSEQ) is a clinical trial in COVID, sponsored by Institute of Tropical Medicine, Belgium.

Who is sponsoring NCT04368143?

NCT04368143 is sponsored by Institute of Tropical Medicine, Belgium.

What condition does NCT04368143 study?

NCT04368143 studies COVID, SARS-CoV 2, Corona Virus Infection, RDT, B Cell.

Is NCT04368143 still recruiting?

NCT04368143 is currently completed. Last updated 2 October 2023.

Last reviewed 2023-10-02 · How we verify

NCT04368143: IMSEQ

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Immune Repertoire Sequencing

Completed Last updated 2 October 2023

What this trial tests

trial in COVID in 84 participants. Completed in 2 December 2021.

Timeline

1 April 2020

Primary endpoint
2 December 2021

2 December 2021

Quick facts

Lead sponsor	Institute of Tropical Medicine, Belgium
Status	Completed
Study type	OBSERVATIONAL
Enrollment	84
Start date	1 April 2020
Primary completion	2 December 2021
Estimated completion	2 December 2021
Sites	1 location across Belgium

Conditions studied

COVID — all drugs for COVID →
SARS-CoV 2 — all drugs for SARS-CoV 2 →
Corona Virus Infection — all drugs for Corona Virus Infection →
RDT — all drugs for RDT →

Sponsor

Institute of Tropical Medicine, Belgium

Who can join

18 and older, any sex, with COVID or SARS-CoV 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This concerns a single-center prospective interventional cohort study. Laboratory-confirmed COVID-19 patients will be asked to donate blood at at least two different timepoints. This will allow us to investigate T and B cell evolutions during the course of infection and recovery. The expected duration of the study is four months or the total duration of the SARS-CoV-2 circulation in Belgium (whichever is shortest).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients.
Bracke A, De Hert E, De Bruyn M, Claesen K, et al · · 2022 · cited 11× · PMID 35283094 · DOI 10.1016/j.cca.2022.03.005
Diagnosing Viral Infections Through T-Cell Receptor Sequencing of Activated CD8+ T Cells.
Vujkovic A, Ha M, de Block T, van Petersen L, et al · · 2024 · cited 5× · PMID 37787611 · DOI 10.1093/infdis/jiad430
Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis.
Claesen K, Sim Y, Bracke A, De Bruyn M, et al · · 2022 · cited 4× · PMID 35329820 · DOI 10.3390/jcm11061494
Leveraging T-cell receptor - epitope recognition models to disentangle unique and cross-reactive T-cell response to SARS-CoV-2 during COVID-19 progression/resolution.
Postovskaya A, Vujkovic A, de Block T, van Petersen L, et al · · 2023 · cited 3× · PMID 37325653 · DOI 10.3389/fimmu.2023.1130876
Leveraging T-cell receptor – epitope recognition models to disentangle unique and cross-reactive T-cell response to SARS-CoV-2 during COVID-19 progression/resolution
Postovskaya A, Vujkovic A, de Block T, van Petersen L, et al · · 2020 · DOI 10.1101/2020.09.09.289355

Verify or expand the search:

Other recruiting trials for COVID

Currently open trials in the same condition.

NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting

Other Institute of Tropical Medicine, Belgium trials

Trials by the same sponsor.

NCT07463040 — Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) · Phase 3 · not yet recruiting
NCT07174648 — Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo. · not yet recruiting
NCT07499739 — Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX) · Phase 4 · not yet recruiting
NCT07342829 — Prospective Follow-up After MVA-BN Booster Vaccination · not yet recruiting
NCT06839989 — An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04368143 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Tropical Medicine, Belgium
Last refreshed: 2 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04368143.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing